Agios Pharmaceuticals - AGIO Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AGIO shares.
View AGIO analyst ratings or view top-rated stocks.

7 equities research analysts have issued 12 month price objectives for Agios Pharmaceuticals' shares. Their AGIO share price forecasts range from $16.00 to $96.00. On average, they expect the company's share price to reach $51.14 in the next twelve months. This suggests a possible upside of 83.4% from the stock's current price.
View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts.

Agios Pharmaceuticals' stock was trading at $32.87 at the beginning of the year. Since then, AGIO stock has decreased by 15.2% and is now trading at $27.88.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our AGIO earnings forecast.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($1.68) earnings per share for the quarter, beating analysts' consensus estimates of ($1.78) by $0.10. The biopharmaceutical company earned $5.58 million during the quarter, compared to analyst estimates of $2.86 million. The firm's revenue was up 5482.0% on a year-over-year basis. During the same quarter last year, the company earned ($1.36) EPS.

11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (6.20%), FMR LLC (5.36%), Price T Rowe Associates Inc. MD (4.65%), Goldman Sachs Group Inc. (3.06%), JPMorgan Chase & Co. (2.57%) and Macquarie Group Ltd. (2.47%). Insiders that own company stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, Darrin Miles, David P Schenkein, Jacqualyn A Fouse and Theodore James Jr Washburn.
View institutional ownership trends.

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGIO stock can currently be purchased for approximately $27.88.

Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.53 billion and generates $203.20 million in revenue each year. The biopharmaceutical company earns $1.60 billion in net income (profit) each year or ($6.72) on an earnings per share basis.

The company employs 390 workers across the globe.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com.